TY - JOUR
T1 - Critical shortage of new antibiotics in development against multidrug-resistant bacteria - Time to react is now
AU - Freire-Moran, Laura
AU - Aronsson, Bo
AU - Manz, Chris
AU - Gyssens, Inge C.
AU - So, Anthony D.
AU - Monnet, Dominique L.
AU - Cars, Otto
N1 - Funding Information:
We acknowledge the contribution to the assessment of substances by the following members of the ECDC-EMA Working Group: Ragnar Norrby, Mair Powell, Otto Cars, Helen Giamarellou and Irja Lutsar. The following colleagues also reviewed the agents found in the database search: Johan Mouton, Gunnar Kahlmeter, Carl Erik Nord and Hartmut Lode. In addition, Murat Akova acted both as a reviewer and as an observer in the ECDC-EMA Working Group appointed by The European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Financial support for this study was provided by EMA and ReAct – Action on Antibiotic Resistance, Uppsala University and Duke University's Program on Global Health and Technology Access. The results in this study have in part been previously presented as a technical report from ECDC and EMA ( ECDC/EMEA, 2009 ).
PY - 2011/4
Y1 - 2011/4
N2 - Two commercial databases (Pharmaprojects and Adis Insight R&D) were queried for antibacterial agents in clinical development. Particular attention was given to antibacterial agents for systemic administration. For each agent, reviewers were requested to indicate whether its spectrum of activity covered a set of selected multidrug-resistant bacteria, and whether it had a new mechanism of action or a new target. In addition, PubMed was searched for antibacterial agents in development that appeared in review articles. Out of 90 agents that were considered to fulfil the inclusion criteria for the analysis, 66 were new active substances. Fifteen of these could be systemically administered and were assessed as acting via a new or possibly new mechanism of action or on a new or possibly new target. Out of these, 12 agents were assessed as having documented in vitro activity against antibiotic-resistant Gram-positive bacteria and only four had documented in vitro activity against antibiotic-resistant Gram-negative bacteria. Of these four, two acted on new or possibly new targets and, crucially, none acted via new mechanisms of action. There is an urgent need to address the lack of effective treatments to meet the increasing public health burden caused by multidrug-resistant bacteria, in particular against Gram-negative bacteria.
AB - Two commercial databases (Pharmaprojects and Adis Insight R&D) were queried for antibacterial agents in clinical development. Particular attention was given to antibacterial agents for systemic administration. For each agent, reviewers were requested to indicate whether its spectrum of activity covered a set of selected multidrug-resistant bacteria, and whether it had a new mechanism of action or a new target. In addition, PubMed was searched for antibacterial agents in development that appeared in review articles. Out of 90 agents that were considered to fulfil the inclusion criteria for the analysis, 66 were new active substances. Fifteen of these could be systemically administered and were assessed as acting via a new or possibly new mechanism of action or on a new or possibly new target. Out of these, 12 agents were assessed as having documented in vitro activity against antibiotic-resistant Gram-positive bacteria and only four had documented in vitro activity against antibiotic-resistant Gram-negative bacteria. Of these four, two acted on new or possibly new targets and, crucially, none acted via new mechanisms of action. There is an urgent need to address the lack of effective treatments to meet the increasing public health burden caused by multidrug-resistant bacteria, in particular against Gram-negative bacteria.
KW - Antibacterial drug development
KW - Antibiotic resistance
KW - Antibiotics
KW - Antimicrobial resistance
KW - ECDC
KW - EMA
KW - Gap-analysis
KW - Multidrug resistant bacteria
KW - Novel antimicrobials
KW - ReAct
UR - http://www.scopus.com/inward/record.url?scp=79955759821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955759821&partnerID=8YFLogxK
U2 - 10.1016/j.drup.2011.02.003
DO - 10.1016/j.drup.2011.02.003
M3 - Article
C2 - 21435939
AN - SCOPUS:79955759821
SN - 1368-7646
VL - 14
SP - 118
EP - 124
JO - Drug Resistance Updates
JF - Drug Resistance Updates
IS - 2
ER -